High safety screening rates prior to immunomodulator initiation at health-system specialty pharmacies: A multisite, prospective, observational cohort study

Clicks: 1
ID: 316447
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #123 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Patients being initiated on treatment with select immunomodulators should be screened for tuberculosis (TB) and hepatitis B virus (HBV). Previous studies found disparities in TB/HBV screening before therapy initiation. Health-system specialty pharmacies (HSSPs) have access to electronic health records and can evaluate infection screening completion. SUMMARY: A multisite, prospective, observational cohort study was conducted at 12 HSSPs. Patients 18 years of age or older prescribed an immunomodulator between March 1 and May 31, 2023, were included. Patients prescribed medications associated with a risk of TB or HBV reactivation within the previous year or referred from a non-health-system provider were excluded. Patients were followed for 6 months. Screening completion was summarized as percentages. Univariate logistic regression models were used to evaluate the association between the number of HSSP services provided and completion of safety screening, and safety screening-related pharmacist interventions. Of 1,597 pharmacy referrals, 737 patients were included. Patients had rheumatological (55.5%; n = 409), dermatological (29%; n = 214), or gastroenterological conditions (15.5%; n = 114). In total, 95.1% of patients (n = 701) had any screening for TB and HBV, and 81.5% (n = 601) completed screenings within 2 years before or 60 days after referral. Screening was completed within 1 year before or 60 days after referral for 75.3% of patients (n = 555). More HSSP services were associated with increased likelihood of completed safety screening (odds ratio [OR], 1.23; P = 0.012) and pharmacist interventions (OR, 2.68; P = 0.04). CONCLUSION: High rates of screening for TB and HBV before immunomodulator therapy initiation were observed in patients referred to HSSPs.
Reference Key
openalex_W7163989674 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kimhouy Tong, Karen C. Thomas, Autumn Zuckerman, Leena Choi, Nicolas Gargurevich, Erica Godley, Rena Gosser, Amanuel Kehasse, Kate Lewis, Jennifer Loucks, Katharine McCarthy, Stephanie Pilat, Gabrielle Plaia, Nancy Rizkalla, Mackenzie VanSice
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag166
URL
https://doi.org/10.1093/ajhp/zxag166
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.